PKC inhibition normalizes the wound-healing capacity of diabetic human fibroblasts

Journal of Clinical Investigation

Volumn 126, Issue 3, 2016, Pages 837-853

  Khamaisi, Mogher ^a,b   Katagiri, Sayaka ^a   Keenan, Hillary ^a   Park, Kyoungmin ^a   Maeda, Yasutaka ^a   Li, Qian ^a   Qi, Weier ^a   Thomou, Thomas ^c   Eschuk, Danielle ^a   Tellechea, Ana ^a   Veves, Aris ^a   Huang, Chenyu ^d   Orgill, Dennis Paul ^e   Wagers, Amy ^c   King, George L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c JOSLIN DIABETES CENTER   (United States)

^d TSINGHUA UNIVERSITY   (China)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MESSENGER RNA; PROTEIN KINASE C DELTA; SMALL INTERFERING RNA; VASCULOTROPIN; PRKCD PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FIBROBLAST; GENE EXPRESSION; GRANULATION TISSUE; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL HYPOXIA; CELL MOTION; CELL PROLIFERATION; COMPLICATION; DIABETIC FOOT; ENZYMOLOGY; GENE SILENCING; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETIC FOOT; FEMALE; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HALF-LIFE; HUMANS; INSULIN; MALE; MICE, NUDE; MIDDLE AGED; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84959898613     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82788     Document Type: Article

References (64)

1. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719-1724.
2. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219-1222.
3. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 2006;116(3):598-606.
4. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83(3):835-870.
5. Brandner JM, Zacheja S, Houdek P, Moll I, Lobmann R. Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model. Diabetes Care. 2008;31(1):114-120.
6. Bishop AJ, Mudge E. A retrospective study of diabetic foot ulcers treated with hyperbaric oxygen therapy. Int Wound J. 2012;9(6):665-676.
7. Markuson M, et al. The relationship between hemoglobin A(1c) values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care. 2009;22(8):365-372.
8. Otranto M, Nascimento AP, Monte-Alto-Costa A. Insulin resistance impairs cutaneous wound healing in mice. Wound Repair Regen. 2013;21(3):464-472.
9. Seitz O, et al. Wound healing in mice with highfat diet-or ob gene-induced diabetes-obesity syndromes: a comparative study. Exp Diabetes Res. 2010;2010:476969.
10. Pence BD, Woods JA. Exercise, obesity, and cutaneous wound healing: evidence from rodent and human studies. Adv Wound Care (New Rochelle). 2014;3(1):71-79.
11. Cheng C, Singh V, Krishnan A, Kan M, Martinez JA, Zochodne DW. Loss of innervation and axon plasticity accompanies impaired diabetic wound healing. PLoS One. 2013;8(9):e75877.
12. Walmsley D, Wales JK, Wiles PG. Reduced hyperaemia following skin trauma: evidence for an impaired microvascular response to injury in the diabetic foot. Diabetologia. 1989;32(10):736-739.
13. Ghanassia E, Villon L, Thuan Dit Dieudonne JF, Boegner C, Avignon A, Sultan A. Long-term outcome and disability of diabetic patients hospitalized for diabetic foot ulcers: a 6.5-year follow-up study. Diabetes Care. 2008;31(7):1288-1292.
14. Zubair M, Malik A, Ahmad J. The impact of creatinine clearance on the outcome of diabetic foot ulcers in north Indian tertiary care hospital. Diabetes Metab Syndr. 2011;5(3):120-125.
15. McEwen LN, Ylitalo KR, Herman WH, Wrobel JS. Prevalence and risk factors for diabetes-related foot complications in Translating Research Into Action for Diabetes (TRIAD). J Diabetes Complications. 2013;27(6):588-592.
16. Tsang MW, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26(6):1856-1861.
17. Greer N, et al. Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review. Ann Intern Med. 2013;159(8):532-542.
18. Hassan WU, Greiser U, Wang W. Role of adiposederived stem cells in wound healing. Wound Repair Regen. 2014;22(3):313-325.
19. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705.
20. Darby IA, Laverdet B, Bonte F, Desmouliere A. Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol. 2014;7:301-311.
21. Driskell RR, et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature. 2013;504(7479):277-281.
22. Thangapazham RL, Darling TN, Meyerle J. Alteration of skin properties with autologous dermal fibroblasts. Int J Mol Sci. 2014;15(5):8407-8427.
23. Brem H, et al. Primary cultured fibroblasts derived from patients with chronic wounds: a methodology to produce human cell lines and test putative growth factor therapy such as GMCSF. J Transl Med. 2008;6:75.
24. Zgheib C, Xu J, Liechty KW. Targeting inflammatory cytokines and extracellular matrix composition to promote wound regeneration. Adv Wound Care (New Rochelle). 2014;3(4):344-355.
25. Keenan HA, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846-2853.
26. Sun JK, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care. 2011;34(4):968-974.
27. Hernandez SL, et al. Characterization of circulating and endothelial progenitor cells in patients with extreme-duration type 1 diabetes. Diabetes Care. 2014;37(8):2193-2201.
28. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319-1331.
29. Kikkawa U, Matsuzaki H, Yamamoto T. Protein kinase C delta (PKC): activation mechanisms and functions. J Biochem. 2002;132(6):831-839.
30. Li Q, et al. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-beta isoform in the endothelium. Circ Res. 2013;113(4):418-427.
31. Bainbridge P. Wound healing and the role of fibroblasts. J Wound Care. 2013;22(8):407-408.
32. Xuan YH, et al. High-glucose inhibits human fibroblast cell migration in wound healing via repression of bFGF-regulating JNK phosphorylation. PLoS One. 2014;9(9):e108182.
33. Hart J, Silcock D, Gunnigle S, Cullen B, Light ND, Watt PW. The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing. Int J Biochem Cell Biol. 2002;34(12):1557-1570.
34. Weiss RA. Autologous cell therapy: will it replace dermal fillers? Facial Plast Surg Clin North Am. 2013;21(2):299-304.
35. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005;366(9498):1725-1735.
36. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest. 2001;107(10):1215-1218.
37. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol. 2003;162(1):303-312.
38. Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (noninsulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res. 1999;291(2-3):93-99.
39. Loot MA, et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol. 2002;81(3):153-160.
40. Pang TT, et al. Inhibition of islet immunoreactivity by adiponectin is attenuated in human type 1 diabetes. J Clin Endocrinol Metab. 2013;98(3):E418-R428.
41. Igarashi M, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest. 1999;103(2):185-195.
42. He Z, et al. Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler Thromb Vasc Biol. 2006;26(4):787-793.
43. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3(1):46-56.
44. Vicent D, et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest. 2003;111(9):1373-1380.
45. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000;6(1):77-86.
46. Xu F, et al. Foxo1 inhibits diabetic mucosal wound healing but enhances healing of normoglycemic wounds. Diabetes. 2015;64(1):243-256.
47. Maeno Y, et al. Inhibition of insulin signaling in endothelial cells by protein kinase C-induced phosphorylation of p85 subunit of phosphatidylinositol 3-kinase (PI3K). J Biol Chem. 2012;287(7):4518-4530.
48. Goren I, et al. Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice. J Invest Dermatol. 2009;129(3):752-764.
49. Lima MH, et al. Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: a double-blind placebo-controlled clinical trial. PLoS One. 2012;7(5):e36974.
50. Park K, et al. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. Mol Cell Biol. 2013;33(16):3227-3241.
51. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25(3):487-496.
52. Leibiger B, et al. Short-term regulation of insulin gene transcription by glucose. Proc Natl Acad Sci U S A. 1998;95(16):9307-9312.
53. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013;123(7):2764-2772.
54. Thangarajah H, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106(32):13505-13510.
55. Duscher D, et al. Transdermal deferoxamine prevents pressure-induced diabetic ulcers. Proc Natl Acad Sci U S A. 2015;112(1):94-99.
56. Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci. 1994;21(4):S3-S7.
57. Shevchenko RV, et al. The in vitro characterization of a gelatin scaffold, prepared by cryogelation and assessed in vivo as a dermal replacement in wound repair. Acta Biomater. 2014;10(7):3156-3166.
58. Succar J, et al. The role of mouse mast cell proteases in the proliferative phase of wound healing in microdeformational wound therapy. Plast Reconstr Surg. 2014;134(3):459-467.
59. Geraldes P, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15(11):1298-1306.
60. Mima A, et al. Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes. Invest Ophthalmol Vis Sci. 2012;53(13):8424-8432.
61. Heit YI, et al. Early kinetics of integration of collagen-glycosaminoglycan regenerative scaffolds in a diabetic mouse model. Plast Reconstr Surg. 2013;132(5):767e-776e.
62. Jung M, et al. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing. J Biol Chem.2013;288(5):3289-3304.
63. Tancharoen S, et al. Cleavage of host cytokeratin-6 by lysine-specific gingipain induces gingival inflammation in periodontitis patients. PLoS One. 2015;10(2):e0117775.
64. Ji R, et al. TAM receptors support neural stem cell survival, proliferation and neuronal differentiation. PLoS One. 2014;9(12):e115140.